Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo

Inclusion Criteria: * Aged 18 to 75 years (inclusive), with no restriction on gender; * Clinically diagnosed with non-segmental vitiligo at screening; * At the screening visit and baseline visit, the Facial Vitiligo Area Scoring Index (F-VASI) is ≥ 0.5 and the Total Vitiligo Area Scoring Index (T-VASI) is ≥ 3; * At the screening visit and baseline visit, the disease is in the progressive stage or stable stage; Exclusion Criteria: * Individuals with a known allergy to Janus kinase inhibitors； * Segmental vitiligo, mixed vitiligo, or undetermined vitiligo； * White hair is present in more than 33% of facial skin lesions due to vitiligo, or in more than 33% of total skin lesions due to vitiligo; * Skin lesions due to vitiligo are restricted to hairless areas, or hairless regions account for ≥30% of the lesion sites (e.g., lips, palms, fingers, labia); * Individuals with other active hypopigmentary conditions during the screening period (including but not limited to Vogt-Koyanagi-Harada syndrome, hypopigmentation associated with malignant tumors \[melanoma and mycosis fungoides\], post-inflammatory hypopigmentation, pityriasis alba \[a mild manifestation of atopic dermatitis\], senile leukoderma \[age-related depigmentation\], chemical/drug-induced leukoderma, ataxia-telangiectasia, tuberous sclerosis complex, melasma, and congenital hypopigmentary disorders \[including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, hereditary symmetrical dyschr…